Infant eczema face cream and preparation method thereof

Abstract

According to the infant eczema face cream and the preparation method thereof, high-content solid lipid is adopted, high sealing performance is provided, the skin hydration effect is enhanced, the skin barrier is repaired, in addition, an emulsion thickening type polymer is matched to assist a natural and safe sucrose ester emulsifier to improve the emulsion stability, introduction of other emulsifiers with the stimulation risk is avoided, and the skin care effect is improved. Under the synergistic effect of the three components, the high sealing performance, the safety and the stability of baby products are considered. The active composition derived from natural plant extracts has a synergistic effect to exert remarkable anti-inflammatory and soothing effects, expression of inflammatory factors is reduced, and certain help is provided for adjuvant therapy of eczema. The baby eczema face cream does not contain pigment, alcohol, hormone, preservative, essence and other sensitization components, is safe and friendly to baby skin, realizes the formula design principle of nature, safety, necessary efficacy and extremely simple formula, aims at externally sealing and repairing a barrier and internally resisting inflammation and relieving skin, and is particularly suitable for being used as a nursing face cream for babies.

Description

Technical Field

[0001] The invention relates to a facial cream for infant eczema and a preparation method thereof. Background Art

[0002] The epidermis and dermis of infants (infants and children) are not yet perfect. The epidermal keratinocytes and granular cells are smaller than those of adults. The thickness of the stratum corneum is 30% thinner than that of adults, and the thickness of the epidermis is 20% thinner. There are fewer intercellular lipids, and the barrier function has not yet fully developed. Although the stratum corneum has a high water content, the epidermal water loss is faster. The imperfect barrier function makes the skin of infants and children more vulnerable to damage from climate, mechanical force, external stimuli, microorganisms, and ultraviolet rays, causing skin problems such as dry skin, chapped skin, eczema, inflammation, and allergies. Among them, eczema is one of the most common skin diseases in infants and children. It is an allergic skin inflammation caused by a variety of internal and external factors. It has itching, erythema, and exudation tendency as the main symptoms. The treatment is more difficult and prone to recurrence. According to the structural characteristics of infant skin, the formula of infant cosmetics should follow the principles of natural safety, necessary efficacy, and minimal formula. The skin of children with eczema is more fragile after being damaged, and improper use of skin care products is more likely to cause various adverse reactions. Therefore, skin care products for children with eczema have higher requirements for safety and efficacy.

[0003] Infant and child eczema is accompanied by skin inflammation and skin barrier damage. Therefore, the skin barrier needs to be repaired during anti-inflammatory treatment to prevent the vicious cycle caused by barrier damage. Studies have shown that plant extracts such as Centella asiatica extract and Ophiopogon japonicus root extract have excellent anti-inflammatory and soothing effects. External use of moisturizing creams containing such plant extracts can improve skin hydration, reduce the expression of inflammatory factors, effectively protect and restore skin barrier function, and reduce the recurrence of chronic eczema.

[0004] Emollients improve the skin barrier function by providing exogenous lipids to the skin. Because children with eczema have less skin lipid secretion and are prone to water loss, they need to pay more attention to occlusion and moisturizing. They can choose more solid lipids with stronger occlusion, such as petrolatum, avocado esters, beeswax, etc., and then compound some safe and stable natural oils and synthetic oils. However, a high content of solid lipids has extremely high requirements on the emulsification ability of the system. It is usually necessary to compound different types of emulsifiers or introduce anionic emulsifiers with irritation risks to achieve emulsification. Although products made with anionic emulsifiers or conventional PEG emulsifiers can effectively guarantee their stability, they are slightly lacking in safety and naturalness for the sensitive skin of infants and children. Obviously, this cannot meet the design principles of natural safety and minimalist formula for infant and child eczema products. The reasonable selection of emulsifiers is very necessary for the safety of infant and child products. For example, alkyl glycosides and sucrose ester emulsifiers used in the food industry are a good choice. The ingredients are natural and safe and do not contain EO. However, their emulsifying properties are slightly weaker, and it is difficult to emulsify large amounts of solid lipids. The shelf life stability of the product cannot be guaranteed. For example, the patent with publication number CN116077357A discloses a moisturizing lotion for infants and young children containing vitamin E and a preparation method thereof, wherein the emollient content is only 0.5-2%, the moisturizing and repairing ability of the product is limited, and the addition of fragrances can easily irritate the fragile skin of infants and young children; the patent with publication number CN 111956563A discloses a multi-effect cream for infants and young children containing surface-treated calamine and a preparation method thereof, and alcohol is used to disinfect the anti-itching parts, which is highly irritating to the skin of infants and young children; the patent with publication number CN 117338644 A discloses a skin anti-cracking lotion containing a high proportion of egg yolk oil and a preparation method thereof, and an anionic emulsifier is compounded to emulsify the high-content egg yolk oil, which poses a use risk to the skin of infants and young children; the patent with publication number CN 115105445 A discloses a moisturizing cream composition for infants and young children that does not contain a PEG emulsifier and a preparation method thereof, and three emulsifiers are compounded to form a stable water-in-oil cream, and the types of emulsifiers are complex.

[0005] Therefore, when developing products for infant eczema, it is important to pay attention to anti-inflammatory effects while repairing the damaged skin barrier. Introducing high-content solid lipids to provide high occlusion to repair the skin barrier is a good choice. However, high-content solid lipids have extremely high requirements on the emulsification ability of the system. How to balance the safety and stability of the system is an urgent problem to be solved. Summary of the invention

[0006] The purpose of the present invention is to overcome the defects of the prior art and provide a baby eczema face cream, which uses a high content of solid lipids to provide high occlusiveness to repair the skin barrier, and is also matched with an emulsifying thickening polymer to assist the natural and safe sucrose ester emulsifier to improve the emulsification stability, taking into account the high occlusiveness, safety and stability of baby products. The combined active composition has excellent soothing and anti-inflammatory effects, achieving the nursing goal of external repair and internal anti-inflammatory of baby eczema skin.

[0007] Another object of the present invention is to provide a method for preparing the baby eczema facial cream.

[0008] A technical solution to achieve the above purpose is: a baby eczema cream, based on 100 parts by total weight, comprising the following components:

[0009]

[0010]

[0011] The mass ratio of the solid lipid to the liquid oil is (1-3):1;

[0012] The active composition consists of 1 to 5 parts of citrus peel extract, 0.5 to 4 parts of gardenia fruit extract and 1 to 6 parts of beta-glucan.

[0013] In the above-mentioned infant eczema facial cream, the emulsifier is sucrose polystearate.

[0014] In the above-mentioned infant eczema facial cream, the moisturizing agent is one or more of glycerin, propylene glycol, dipropylene glycol, butylene glycol, 1,2-pentanediol and sodium hyaluronate.

[0015] In the above-mentioned infant eczema facial cream, the thickener is hydroxyethyl acrylate / sodium acryloyldimethyl taurate copolymer.

[0016] In the above-mentioned infant eczema facial cream, the solid lipid is one or more of avocado butter, petrolatum, hydrogenated coconut glycerides, beeswax, cetearyl alcohol and behenyl alcohol.

[0017] The above-mentioned infant eczema cream, wherein the liquid oil is one or more of squalane, tridecyl trimellitate, caprylic / capric triglyceride, pentaerythritol tetra(ethylhexanoate), hydrogenated polyisobutene, flatwood oil, tocopherol acetate, unsaponifiable matter of sunflower seed oil and polydimethylsiloxane.

[0018] In the above-mentioned infant eczema facial cream, the antioxidant is p-hydroxyacetophenone.

[0019] The present invention also provides a method for preparing a baby eczema cream, comprising the following steps:

[0020] S1, add water into the main preparation tank, then add the moisturizer and thickener into the main preparation tank in sequence, stir and mix evenly, and heat to 80℃~85℃ for insulation;

[0021] S2, adding the emulsifier, solid lipid and liquid oil into the oil phase tank, stirring and mixing them evenly, and heating to 80°C to 85°C for insulation;

[0022] S3, adding the raw materials in the oil phase tank into the main preparation tank, homogenizing and emulsifying at 80°C to 85°C for 10 minutes, and then cooling;

[0023] S4, when the temperature of the main preparation tank drops to 70℃~75℃, add antioxidant, stir and mix evenly, and continue to cool down;

[0024] S5, when the temperature of the main preparation tank drops to 40°C to 45°C, add the active composition, stir and mix evenly, and continue to cool;

[0025] S6. When the temperature of the main preparation tank drops below 38°C, filter out the material to obtain the baby eczema cream.

[0026] The technical scheme of the baby eczema cream and the preparation method thereof of the present invention has the following beneficial effects:

[0027] (1) The baby eczema cream of the present invention is designed to target the skin characteristics of baby eczema. It uses a high content of solid lipids to provide high occlusiveness, enhance skin hydration, and repair the skin barrier. In addition, it is combined with an emulsifying and thickening polymer to assist the natural and safe sucrose ester emulsifier to improve the emulsification stability and avoid the introduction of other emulsifiers with irritation risks. The three work synergistically to take into account the high occlusiveness, safety, and stability of baby products.

[0028] (2) The active composition is composed of gardenia fruit extract, β-glucan and citrus peel extract, which exerts soothing and anti-inflammatory effects. The active composition derived from natural plant extracts synergistically exerts significant anti-inflammatory and soothing effects, reduces the expression of inflammatory factors, and is helpful for the auxiliary treatment of eczema.

[0029] (3) The baby eczema cream of the present invention does not contain allergenic ingredients such as pigments, alcohol, hormones, preservatives and fragrances, is safe and friendly to baby skin, and realizes the formula design principles of natural safety, essential efficacy and extremely simple formula. It can seal and repair the barrier from the outside and relieve inflammation and soothe the skin from the inside, and is particularly suitable as a care cream for babies and children. BRIEF DESCRIPTION OF THE DRAWINGS

[0030] Figure 1 Microscope photos (200X) of the finished preparations of Example 1 and Comparative Examples 1-2;

[0031] Figure 2 The effect of the test substance on the migration of zebrafish neutrophils (quantification);

[0032] Figure 3 It is the effect of the test substance on the migration of zebrafish neutrophils (phenotype). DETAILED DESCRIPTION

[0033] In order to enable those skilled in the art to better understand the technical solution of the present invention, its specific implementation method is described in detail below with reference to the accompanying drawings.

[0034] Examples 1 to 4 and Comparative Examples 1 to 2 all provide a baby eczema cream, and the specific formula is shown in Table 1.

[0035] Table 1, formula of baby eczema cream of Examples 1 to 4 and Comparative Examples 1 to 2:

[0036]

[0037]

[0038] Note: The above examples and comparative examples are all based on 100 parts by mass.

[0039] The baby eczema creams of Examples 1 to 4 and Comparative Examples 1 to 2 were prepared by the following preparation method:

[0040] S1. Add water to the main preparation tank, then add the moisturizer and thickener to the main preparation tank in sequence, stir and mix evenly, and heat to 80℃~85℃;

[0041] S2, adding emulsifier, solid lipid and liquid oil into the oil phase tank, stirring and mixing evenly, and heating to 80°C to 85°C for insulation;

[0042] S3, adding the raw materials in the oil phase tank into the main preparation tank, homogenizing and emulsifying at 80℃~85℃ for 10min, and then cooling down;

[0043] S4. When the temperature of the main preparation tank drops to 70℃~75℃, add antioxidant, stir and mix evenly, and continue to cool down;

[0044] S5. When the temperature of the main preparation tank drops to 40°C to 45°C, add the active composition, stir and mix evenly, and continue to cool;

[0045] S6. When the temperature of the main preparation tank drops below 38°C, filter out the material to obtain the final preparation product.

[0046] Comparative Examples 3 to 8 all provide a baby eczema cream, and the specific formula is shown in Table 2.

[0047] Table 2, formula of baby eczema cream of comparative examples 3 to 8:

[0048]

[0049]

[0050] Note: The above comparative examples are all based on 100 parts by mass.

[0051] The preparation method of the baby eczema cream of Comparative Examples 3 to 8 is the same as that of Examples 1 to 4

[0052] 1. Stability test

[0053] The stability of the samples obtained in Examples 1-4 and Comparative Examples 1-2 was investigated with reference to the QBT1857-2013 "Moisturizing Cream" standard. The samples were placed at 25°C, 5°C, -15°C, 40°C, 49°C and hot and cold cycle conditions for 3 months. After the samples returned to room temperature, the appearance, odor and color changes of the samples were observed. The results of the 3-month stability investigation are shown in Tables 3 and Figure 1 shown.

[0054] Table 3, stability test results:

[0055]

[0056] Note: During the 3-month inspection period, there was no significant change in the color and smell of the samples.

[0057] According to Table 3, it can be seen that after the samples obtained in Examples 1 to 4 were tested for 3 months under the conditions of -15°C, 5°C, 25°C, 40°C, and 49°C, and the temperature cycle, there was no oil-water separation phenomenon after the material body returned to room temperature, and there was no obvious difference in properties before the experiment, and the stability test was passed. However, the sample obtained in Comparative Example 1 showed a slight water-oil separation phenomenon under high and low temperature conditions, and the sample obtained in Comparative Example 2 had different degrees of water-oil separation under each test condition. Figure 1 It can be seen from the microscope photos that the emulsified particles of the sample obtained in Example 1 of the present invention have a smaller particle size and are evenly distributed, while the emulsified particles of the samples obtained in Comparative Examples 1 to 2 have a larger particle size, are unevenly distributed, and the oil phase has agglomeration.

[0058] The above results show that compared with single thickening polymers, emulsifying thickening polymers can better enhance the emulsification stability in the system. They can assist the natural and safe sucrose ester emulsifier in emulsifying high-content solid lipids. There is no need to introduce other types of emulsifiers to ensure the stability of the product, thereby reducing the adverse effects of emulsifiers and reducing the rate of skin allergies.

[0059] 2. Security Testing

[0060] Carry out safety tests on samples in accordance with the Technical Specifications for Safety of Cosmetics (2015 edition).

[0061] Multiple skin irritation / corrosion test method:

[0062] Three healthy adult white New Zealand rabbits are preferred. The animals must adapt to the experimental animal room environment for at least 3 days before the test. Before the test, the hair on both sides of the dorsal spine of the experimental animals is cut off, and the hair removal range is 3cm×3cm each, and the application area is 2.5cm×2.5cm. Take about 0.5mL (g) of the test substance and apply it on one side of the skin. When the test substance is prepared with a non-irritating solvent, the other side is applied with a solvent as a control. Apply once a day for 14 consecutive days. Starting from the second day, the hair should be cut before each application, and the residual test substance should be removed with water or a non-irritating solvent. Observe the results after one hour and score according to Table 4. The control area and the test area are treated in the same way. Calculate the average score of each animal per day according to the following formula, and determine the skin irritation intensity according to Table 5.

[0063] Average score per animal per day = (∑ erythema and edema score / number of animals tested) / 14

[0064] Table 4, skin irritation reaction scoring table:

[0065]

[0066]

[0067] Table 5, skin irritation intensity classification table:

[0068]

[0069] Acute eye irritation / corrosion test method:

[0070] Three healthy adult white New Zealand rabbits are preferred. Animals must adapt to the experimental animal room environment for at least 3 days before the test. Both eyes of the test animals are examined within 24 hours before the start of the test (including the use of sodium fluorescein for examination). Animals with eye irritation symptoms, corneal defects and conjunctival damage cannot be used for the test. Gently pull open the lower eyelid of one eye of the rabbit, drip (or apply) 0.1 mL of the test substance into the conjunctival sac, and passively close the upper and lower eyelids for 1 second to prevent the loss of the test substance. The other eye is not treated as a self-control. 30 seconds after the test substance is dripped into the rabbit eye, rinse with sufficient water with a fast flow rate but without causing damage to the animal eye for at least 30 seconds. Examine the animal eyes 1, 24, 48, 72 hours after the test substance is dripped, as well as on the 4th and 7th days. If no irritation reaction occurs within 72 hours, the test can be terminated. If corneal involvement or other eye irritation is found, and the damage does not recover within 7 days, the observation time should be extended to determine the reversibility or irreversibility of the damage, generally not more than 21 days, and observation reports for 7 days, 14 days and 21 days should be provided. A magnifying glass, handheld slit lamp, biological microscope or other applicable instruments and equipment can be used to check the eye irritation reaction. After the 24-hour observation and recording, the eyes of all animals should be further examined with sodium fluorescein.

[0071] In each examination, the score of eye irritation reaction should be recorded according to the scoring standard of eye damage in Table 6.

[0072] Table 6, Scoring criteria for eye damage:

[0073]

[0074]

[0075] Evaluation of results: The maximum integrated mean value and recovery time of the stimulation response of the cornea, iris or conjunctiva of the animals at the observation time points of 24, 48 or 72 hours after administration of the test substance are used to evaluate the stimulation intensity of the test substance on the eye according to the eye irritation response classification in Table 7.

[0076] Table 7, product eye irritation reaction classification table:

[0077]

[0078]

[0079] Note: When the scores of cornea, iris and conjunctiva are 0, it can be judged as non-irritating.

[0080] The results of multiple skin irritation / acute eye irritation tests on rabbits are summarized in Table 8.

[0081] Table 8, Results of multiple skin irritation / acute eye irritation tests on rabbits:

[0082]

[0083] Note: The test concentration of the test substance is directly measured.

[0084] It can be seen from Table 8 that the multiple skin / acute eye irritation test results of samples of Examples 1-4 are all non-irritating. Sucrose ester emulsifier has a high safety index and is suitable for the development of baby products.

[0085] Skin occlusive patch test:

[0086] The samples obtained in Examples 1-4 were subjected to human skin patch tests.

[0087] At least 30 subjects will be selected to participate in the trial according to the subject inclusion criteria.

[0088] Select qualified spot test equipment with an area not exceeding 50mm and a depth of about 1mm. Place the test substance in the small chamber of the spot tester, with an amount of about 0.020g-0.025g (solid or semi-solid) or 0.020mL-0.025mL (liquid). When the test substance is the original cosmetic product, the control well is a blank control (no substance is placed). When the test substance is a diluted cosmetic, the diluent of the cosmetic is used in the control well. Apply the spot tester with the test substance to the back or curved side of the forearm of the subject with low-allergenic tape, and press it lightly with the palm of your hand to evenly apply it to the skin for 24 hours. Observe the skin reaction according to the standards in Table 9 30 minutes (after the indentation disappears), 24 hours and 48 hours after removing the test substance spot tester, and record the observation results in Table 10.

[0089] Table 9, skin closure patch test skin reaction grading standard:

[0090]

[0091] Table 10, test results table:

[0092]

[0093] The results of the human skin patch test showed that no adverse skin reactions occurred in any of the 30 subjects, indicating that Examples 1-4 of the present invention are relatively mild and non-irritating.

[0094] 3. Zebrafish Anti-inflammatory Efficacy Test

[0095] The samples obtained in Example 1 and Comparative Examples 3-8 were subjected to zebrafish anti-inflammatory efficacy tests to determine their efficacy in treating eczema. The changes in the number of neutrophils in the skin of zebrafish Tg (mpx:dsRED) before and after treatment with neutrophil red fluorescence markers were used to detect whether the samples had anti-inflammatory and soothing effects.

[0096] The zebrafish breeding method was carried out according to "The zebrafish book". The water temperature was maintained at about 28.5℃, with 14 hours of light and 10 hours of darkness per day, and feeding once in the morning and evening. The night before collecting embryos, one female and two male fish were placed in the spawning tank, separated by a partition and placed in a dark environment. The next morning, the partition was removed after the lights were turned on, and the embryos were collected after the spawning was completed. The embryos were placed in egg water and cultured in a light incubator at 28.5℃.

[0097] On the day of embryo collection, about 7-8 hpf, the embryos were thoroughly washed with a new solution, and the embryos in poor condition were removed. Fresh egg water was replaced and the cells were cultured in a 28.5°C incubator until 3 dpf (poor embryos were picked out in time during the culture period, and fresh egg water was replaced every day). The 3 dpf zebrafish were randomly divided into groups, with 15 in each group: normal control group: containing zebrafish and standard dilution water; model control group: containing zebrafish and 1 μM copper sulfate solution; test group: containing zebrafish, 1 μM copper sulfate solution and the test substance. The test substance was set up in multiple different concentration groups as needed. According to the experimental requirements, a sufficient number of 72 hpf zebrafish with consistent developmental conditions were pre-screened, and the zebrafish were randomly assigned to a six-well plate, with 15 per well. The standard dilution water in the 6-well plate was removed without harming the embryos, and then 3 mL of the test solution was quickly added to each well. After thorough mixing, the culture plate panel was covered and wrapped with aluminum foil, and incubated in a 28°C biochemical incubator in the dark for 2 hours.

[0098] Neutrophil red fluorescence labeled zebrafish (Tg(mpx:dsRED)) can emit red fluorescence in vivo, so the migration and other behaviors of neutrophils in living zebrafish can be directly observed under a stereo fluorescence microscope. After the incubation, zebrafish were randomly selected from zebrafish with normal phenotype and behavior, fixed with 3% methylcellulose, observed and photographed under a stereo fluorescence microscope. All zebrafish photography results must be completed under the same instrument and environmental conditions, and the body position of the zebrafish should be consistent.

[0099] The anti-inflammatory and soothing efficacy of the sample was calculated according to the following formula: Anti-inflammatory and soothing efficacy (%) = (N (model control group) - N (test group of the test substance)) / (N (model control group) - N (normal control group)) * 100%

[0100] *N is the number of neutrophils in the skin

[0101] Test results:

[0102] Under the above experimental conditions, the experimental data were statistically analyzed, and the results of the anti-inflammatory efficacy of the test substances are shown in Table 11.

[0103] Table 11, test results of anti-inflammatory efficacy of the tested substances:

[0104]

[0105]

[0106] Typical figures of anti-inflammatory and soothing effects obtained under the above experimental conditions are shown in Figure 2 and Figure 3 The number of zebrafish neutrophils in the Example 1 group was significantly reduced compared with the model group. The sample obtained in Example 1 had significant anti-inflammatory and soothing effects, while the anti-inflammatory and soothing abilities of Comparative Examples 3-8, which did not add any of the citrus peel extract, gardenia fruit extract, and β-glucan, were all worse than those of Example 1, with significant differences. This indicates that the active composition of the present invention achieves excellent anti-inflammatory and soothing effects through synergistic effects.

[0107] 4. Human efficacy test

[0108] The samples obtained in Example 1 were subjected to human efficacy tests.

[0109] Test plan:

[0110] 31 subjects were selected (screened by lactic acid stinging), and each subject used the test product for 28 days. Product effect feedback was provided by instrumental evaluation and quantitative questionnaires. Efficacy, skin condition and satisfaction were evaluated before using the test product and after 14 and 28 days of use.

[0111] Evaluation parameters:

[0112] 1.VISIA CR is used for facial image acquisition and red zone analysis

[0113] 2. Tewameter TM Hex is used to detect the transepidermal water loss rate of the skin

[0114] 3. Skin moisture content tester Corneometer CM825 is used to detect the moisture content of the skin stratum corneum

[0115] 4. Ultrasonic skin imaging device DermaLab Combo is used to detect dermal thickness, dermal density and epidermal thickness, epidermal density

[0116] 5. Lactic acid sting

[0117] 6. Subject Self-Assessment

[0118] Directions:

[0119] Twice a day, once in the morning and once in the evening, apply an appropriate amount of this product evenly on the face and body skin, especially on dry areas, and gently massage until absorbed.

[0120] Questionnaire filling:

[0121] Fill out the evaluation questionnaire after using the product for 14 and 28 consecutive days.

[0122] The results of the instrumental evaluation after using the product for 14 days and 28 days are shown in Table 12, the subjects' self-evaluation (skin condition) is shown in Table 13, and the subjects' self-evaluation (satisfaction) is shown in Table 14.

[0123] Table 12, Instrument Evaluation Table:

[0124]

[0125]

[0126] *Number of valid samples = 31

[0127] Table 13, self-assessment of subjects (skin condition):

[0128]

[0129]

[0130] *Number of valid samples = 31

[0131] Table 14, Subjects' Self-Assessment (Satisfaction) Table:

[0132] Evaluation index name 14 days recognition 28 days recognition Soothes skin redness after use 87％ 97％ Soothes itching / stinging / burning after use 90％ 97％ Improve skin recurrence / sensitivity / irritation after use 90％ 97％ Improves dryness / flaking / roughness of the skin after use 94％ 100％ Effectively reduce skin discomfort after use 84％ 97％ Moisturizing effect is obvious after use 84％ 100％ Skin feels soft after use 84％ 97％ Skin becomes smooth after use 84％ 97％ Skin becomes moisturized after use 94％ 100％ Skin looks healthier after use 84％ 97％ Effectively relieve itching after use 77％ 97％ Effectively repairs skin after use 84％ 97％ Strengthen skin barrier after use 87％ 97％ The product is suitable for sensitive skin 100％ 100％ The product is mild and non-irritating 100％ 100％

[0133] *Number of valid samples = 31

[0134] 31 subjects used the product for 28 consecutive days as instructed. The evaluation results showed that the product has soothing, moisturizing and repairing effects, and that the product is suitable for sensitive skin and is gentle and non-irritating.

[0135] In the baby eczema cream, gardenia fruit extract, β-glucan and citrus peel extract are used to form an active composition (gardenia fruit extract, β-glucan and citrus peel extract are mixed together in proportion to obtain an active composition), which has soothing and anti-inflammatory effects. The effects of these three components are as follows:

[0136] Synephrine, an alkaloid, is found in the fruits of several trees in the Rutaceae family, including bitter orange, Seville orange, sour orange, green orange, unripe bitter orange, also known as "citrus aurantium" and "honey orange". As a low molecular weight compound, synephrine may have multiple targets. In the past, a large number of quantitative proteomics and bioinformatics analyses as well as in vitro and in vivo experiments have revealed that synephrine regulates multiple sets of genes and targets related to inflammation. Studies have shown that citrus synephrine extracted from citrus peel can inhibit IL-4-induced STAT6 phosphorylation, thereby inhibiting the JAK / STAT signaling pathway and eosinophil recruitment. This biological process is similar to the published mechanism studies of eczema treatment drugs.

[0137] A large number of studies on gardenia have shown that gardenia glycosides extracted from gardenia fruit can play an anti-infection and immunomodulatory role by reducing the levels of inflammatory cytokines. For example, gardenia glycosides can reduce the levels of IL-1β and TNF-α, thereby reducing microglial damage. Gardenia glycosides can downregulate the secretion levels of proinflammatory cytokines interferon-γ, IL-6, and IL-17 in rats with rheumatoid arthritis, upregulate the levels of anti-inflammatory cytokines IL-4 and transforming growth factor β1, restore the dynamic balance between proinflammatory / anti-inflammatory cytokines, reduce the cytokine secretion levels of Th17 cells, and increase the cytokine levels of Treg cells.

[0138] β-glucan can significantly affect the immune response of helper T cells, thereby effectively inhibiting allergic reactions such as eczema dermatitis and reducing the probability of eczema in infants and young children. β-glucan can promote the migration of human keratinocytes (HaCaT) and human skin fibroblasts (HDFa), and accelerate wound closure and re-epithelialization in mouse models. In addition, the anti-inflammatory and anti-irritation properties of β-glucan help relieve inflammation and redness, soothe irritated skin, and are an effective auxiliary treatment for mild atopic dermatitis (eczema).

[0139] In summary, the baby eczema cream of the present invention is aimed at the skin characteristics of baby eczema, adopts high-content solid lipids, provides high closure, enhances skin hydration, repairs skin barrier, and is matched with emulsified thickening polymer to assist natural and safe sucrose ester emulsifier to improve emulsification stability, avoids introducing other emulsifiers with irritation risk, and the three act synergistically, taking into account the high closure, safety and stability of baby products. The active composition derived from natural plant extracts acts synergistically to exert significant anti-inflammatory and soothing effects, reduce the expression of inflammatory factors, and has certain help to the auxiliary treatment of eczema. The baby eczema cream of the present invention does not contain sensitizing ingredients such as pigments, alcohol, hormones, preservatives and essences, is safe and friendly to baby skin, realizes the formula design principles of natural safety, necessary efficacy and extremely simple formula, and is intended to close and repair barriers outside and relieve skin from internal anti-inflammatory, and is particularly suitable as a nursing cream for baby use.

[0140] Those skilled in the art should recognize that the above embodiments are only used to illustrate the present invention, and are not intended to limit the present invention. As long as they are within the spirit of the present invention, any changes or modifications to the above embodiments will fall within the scope of the claims of the present invention.

Claims

1. A baby eczema cream, characterized in that: The total weight is 100 parts, including the following components: The mass ratio of the solid lipid to the liquid oil is (1-3):1; The active composition consists of 1 to 5 parts of citrus peel extract, 0.5 to 4 parts of gardenia fruit extract and 1 to 6 parts of beta-glucan.

2. The baby eczema cream according to claim 1, characterized in that: The emulsifier is sucrose polystearate.

3. The baby eczema facial cream according to claim 1, characterized in that: The moisturizing agent is one or more of glycerin, propylene glycol, dipropylene glycol, butylene glycol, 1,2-pentanediol and sodium hyaluronate.

4. The baby eczema facial cream according to claim 1, characterized in that: The thickener is hydroxyethyl acrylate / sodium acryloyldimethyl taurate copolymer.

5. The baby eczema facial cream according to claim 1, characterized in that: The solid lipid is one or more of avocado butter, petrolatum, hydrogenated coconut glycerides, beeswax, cetearyl alcohol and behenyl alcohol.

6. The baby eczema facial cream according to claim 1, characterized in that: The liquid oil is one or more of squalane, tridecyl trimellitate, caprylic / capric triglyceride, pentaerythritol tetra(ethylhexanoate), hydrogenated polyisobutene, sphenanthene oil, tocopherol acetate, unsaponifiable matter of sunflower seed oil and polydimethylsiloxane.

7. The baby eczema facial cream according to claim 1, characterized in that: The antioxidant is p-hydroxyacetophenone.

8. A method for preparing the baby eczema cream according to claim 1, characterized in that: The following steps are involved: S1, add water into the main preparation tank, then add the moisturizer and thickener into the main preparation tank in sequence, stir and mix evenly, and heat to 80℃~85℃ for insulation; S2, adding the emulsifier, solid lipid and liquid oil into the oil phase tank, stirring and mixing them evenly, and heating to 80°C to 85°C for insulation; S3, adding the raw materials in the oil phase tank into the main preparation tank, homogenizing and emulsifying at 80°C to 85°C for 10 minutes, and then cooling; S4, when the temperature of the main preparation tank drops to 70℃~75℃, add antioxidant, stir and mix evenly, and continue to cool down; S5, when the temperature of the main preparation tank drops to 40°C to 45°C, add the active composition, stir and mix evenly, and continue to cool; S6. When the temperature of the main preparation tank drops below 38°C, filter out the material to obtain the baby eczema cream.

Images